Abstract: A sensor comprising a whisker shaft and a follicle is provided. The shaft has a root end and a tip end and the shaft tapers from the root end to the tip end so that the root end is wider and the tip end is narrower. The root end is pivotably mounted in the follicle.

Abstract: A sensor comprising a whisker shaft and a follicle is provided. The shaft has a root end and a tip end and the shaft tapers from the root end to the tip end so that the root end is wider and the tip end is narrower. The root end is pivotably mounted in the follicle.

Abstract: A sensor comprising a whisker shaft and a follicle is provided. The shaft has a root end and a tip end and the shaft tapers from the root end to the tip end so that the root end is wider and the tip end is narrower. The root end is pivotably mounted in the follicle.

Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.

Abstract: Use of a radiolabelled form of 7-chloro-?/?,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4/?/?pyridazino[4,5-b]indole-1-acetamide as a biomarker for the detection, in an individual, of PBR levels associated with normal and pathological conditions. Method for the detection of PBR levels associated with normal and pathological conditions. Diagnostic kit.

Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.

Abstract: An emission test system may include at least one controller configured to determine, directly or indirectly, a quantity of diluted exhaust sample in a container at the completion of an emissions test, and to cause additional diluent gas to be added to the container based on the determined quantity.

Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.

Abstract: The invention is directed to a single moored offshore marine turbine assembly having a central control vessel which includes a main vessel tethered to a control buoy. The main vessel having a first cap, a corresponding second cap and a tubular shell positioned between both the first cap and second cap. The tubular shell contains one or more vertical partitions to assist in ballasting. The control buoy includes a compressor and an air conduit which forces air into the main vessel through a manifold. A hollow suction caisson affixes the central control vessel to the ocean floor. A taut line mooring secures the suction caisson to the main vessel. Electricity is generated via a turbine shroud assembly having a conical shroud and a hydro-turbine. By attaching a plurality of turbine shroud assemblies in series via cables, a horizontal turbine array is formed resulting in a simple, economical and safe layout.

Abstract: The invention is directed to a single moored offshore marine turbine assembly having a central control vessel which includes a main vessel tethered to a control buoy. The main vessel having a first cap, a corresponding second cap and a tubular shell positioned between both the first cap and second cap. The tubular shell contains one or more vertical partitions to assist in ballasting. The control buoy includes a compressor and an air conduit which forces air into the main vessel through a manifold. A hollow suction caisson affixes the central control vessel to the ocean floor. A taut line mooring secures the suction caisson to the main vessel. Electricity is generated via a turbine shroud assembly having a conical shroud and a hydro-turbine. By attaching a plurality of turbine shroud assemblies in series via cables, a horizontal turbine train is formed resulting in a simple, economical and safe layout.

Abstract: An emission test system may include at least one controller configured to determine, directly or indirectly, a quantity of diluted exhaust sample in a container at the completion of an emissions test, and to cause additional diluent gas to be added to the container based on the determined quantity.

Abstract: The invention is directed to a single moored offshore marine turbine assembly having a central control vessel which includes a main vessel tethered to a control buoy. The main vessel having a first cap, a corresponding second cap and a tubular shell positioned between both the first cap and second cap. The tubular shell contains one or more vertical partitions to assist in ballasting. The control buoy includes a compressor and an air conduit which forces air into the main vessel through a manifold. A hollow suction caisson affixes the central control vessel to the ocean floor. A taut line mooring secures the suction caisson to the main vessel. Electricity is generated via a turbine shroud assembly having a conical shroud and a hydro-turbine. By attaching a plurality of turbine shroud assemblies in series via cables, a horizontal turbine array is formed resulting in a simple, economical and safe layout.

Abstract: An emission test system may include at least one controller configured to determine, directly or indirectly, a quantity of diluted exhaust sample in a container at the completion of an emissions test, and to cause additional diluent gas to be added to the container based on the determined quantity.

Abstract: The invention is directed to a single moored offshore marine turbine assembly having a central control vessel which includes a main vessel tethered to a control buoy. The main vessel having a first cap, a corresponding second cap and a tubular shell positioned between both the first cap and second cap. The tubular shell contains one or more vertical partitions to assist in ballasting. The control buoy includes a compressor and an air conduit which forces air into the main vessel through a manifold. A hollow suction caisson affixes the central control vessel to the ocean floor. A taut line mooring secures the suction caisson to the main vessel. Electricity is generated via a turbine shroud assembly having a conical shroud and a hydro-turbine. By attaching a plurality of turbine shroud assemblies in series via cables, a horizontal turbine train is formed resulting in a simple, economical and safe layout.

Abstract: Use of a radiolabelled form of 7-chloro-?/,?/,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4/-/-pyridazino[4,5-b]indole-1-acetamide as a biomarker for the detection, in an individual, of PBR levels associated with normal and pathological conditions. Method for the detection of PBR levels associated with normal and pathological conditions. Diagnostic kit.

Abstract: An emission test system may include at least one controller configured to determine, directly or indirectly, a quantity of diluted exhaust sample in a container at the completion of an emissions test, and to cause additional diluent gas to be added to the container based on the determined quantity.

Abstract: The present invention relates to the use of novel derivatives of general formula (I) in which R3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(?NH)R1 or C(?NH)NR1 radical; R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl, to treat a disease selected from the group consisting of: neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hy

Abstract: The present invention relates to novel derivatives of general formula (I) in which R3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(?NH)R1 or C(?NH)NR1 radical; R5 and R6 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl.

Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.

Abstract: The present invention relates to the use of novel derivatives of general formula (I) in which R3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(?NH)R1 or C(?NH)NR1 radical; R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl, to treat a disease selected from the group consisting of: neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential h